Does plasma exchange improve symptoms in myasthenia gravis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 3, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Does Plasma Therapy Improve Myasthenia Gravis?

Yes, plasma exchange (plasmapheresis) is highly effective for treating moderate to severe myasthenia gravis, particularly in myasthenic crisis, impending crisis, and preparation for thymectomy, and should be initiated promptly in Grade 3-4 disease.

Treatment Algorithm Based on Disease Severity

Grade 2 (Mild-Moderate Generalized Weakness)

  • Start with pyridostigmine (30 mg PO three times daily, titrate to maximum 120 mg four times daily)
  • Add corticosteroids (prednisone 1-1.5 mg/kg PO daily) if symptoms persist
  • Plasma exchange is NOT routinely indicated at this stage 1
  • Hold immune checkpoint inhibitors if applicable; may resume only after symptom resolution

Grade 3-4 (Severe Disease/Crisis)

Plasma exchange is strongly recommended for:

  • Myasthenic crisis (respiratory compromise)
  • Impending crisis
  • Rapidly progressive symptoms
  • Dysphagia, facial weakness, or respiratory muscle weakness
  • Pre-thymectomy preparation 1, 2, 3

Protocol specifics:

  • 5 sessions over 5 days (standard regimen)
  • Volume: 200-250 ml plasma/kg body weight per session 4
  • Can be performed via peripheral venous access in 83% of patients 5
  • Equally effective as IVIG (2 g/kg over 5 days), but plasma exchange may be preferred when rapid response is critical 1

Clinical Evidence Supporting Plasma Exchange

The evidence demonstrates immediate clinical benefits across multiple studies:

  • Response rate: 57-78% of patients show significant improvement 2, 3, 5
  • All patients showed immediate benefits after each plasma exchange cycle in Indian cohort studies 2, 3
  • Respiratory symptoms respond best (72% response rate), while extraocular symptoms are least responsive (8%) 6

Predictors of Good Response

Two independent factors predict better outcomes 7:

  • Symptom onset ≤3 days before plasma exchange
  • Age <50 years at time of treatment

Additional favorable factors include 6:

  • Presence of thymoma (100% vs 50% response)
  • High AChR-antibody concentration (37.37 vs 25.4 nmol/L)

Safety Profile

Plasma exchange is safe and well-tolerated in myasthenia gravis 5:

  • 55% of patients have no complications
  • 45% experience mild-moderate reactions (primarily citrate reactions and peripheral vascular issues, easily managed)
  • 90% can be treated in outpatient settings
  • Severe adverse events are rare (approximately 2-5%) 2, 3, 5
  • Age and comorbidities do NOT predict adverse reactions 5

Mechanism of Action

Plasma exchange works through 7, 6:

  • Rapid removal of pathogenic AChR antibodies
  • Decreased immunoglobulin and complement levels
  • Immune modulation: decreased IL-17A and IFN-γ, increased IL-10
  • Reduction in CD19+ B cells in responders

Critical Management Points

When to Admit to ICU

All Grade 3-4 patients warrant immediate hospital admission with ICU-level monitoring capability 8, 1:

  • Impending respiratory insufficiency
  • Severe autonomic dysfunction
  • Severe swallowing dysfunction/diminished cough reflex
  • Rapidly progressive weakness

Concurrent Treatment

  • Continue corticosteroids during plasma exchange 1
  • Frequent pulmonary function monitoring (vital capacity, negative inspiratory force)
  • Daily neurologic evaluation
  • Avoid medications that worsen myasthenia: β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, macrolides 8, 1

Plasma Exchange vs IVIG

Both are equally effective 4, but plasma exchange may be preferred when:

  • Rapid response is critical (myasthenic crisis)
  • Cost is a major consideration (plasma exchange is less expensive than IVIG in many settings)
  • Patient has thymoma or high AChR-antibody levels (better predictors of plasma exchange response) 6

IVIG may be preferred when:

  • Plasma exchange expertise/equipment unavailable
  • Peripheral venous access is difficult
  • Patient preference for easier administration 4

Common Pitfalls to Avoid

  1. Delaying plasma exchange in Grade 3-4 disease - Early initiation (≤3 days from symptom onset) predicts better outcomes 7
  2. Using plasma exchange for mild (Grade 2) disease - Not indicated; start with pyridostigmine and corticosteroids 1
  3. Combining plasma exchange followed by IVIG - No more effective than either alone 4
  4. Continuing medications that worsen myasthenia - Review and stop β-blockers, fluoroquinolones, aminoglycosides, macrolides 8, 1
  5. Inadequate respiratory monitoring - Frequent pulmonary function assessment is mandatory in all severe cases 1

Special Populations

Pregnancy: Neither plasma exchange nor IVIG is contraindicated, though IVIG may be preferred due to simpler monitoring requirements 4

Children: Follow adult protocols; IVIG often preferred due to greater discomfort with plasma exchange in pediatric patients 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.